Header
Rhode Island
IDeA Network of Biomedical Research Excellence
INBRE Menu
RI-INBRE > Research Core > Molecular Toxicology > John Williams

John Williams

Arylphosphonium Salt Conjugates: Diagnostic, Cell-Imaging Anticancer Agents; Synthesis and Screening (2012 - Present)

Investigator:  John Williams, Rhode Island College


Abstract:
  Arylphosphonium salts (APS) are cytotoxic lipophilic cations that can cross cell membranes. They interact with DNA, both nuclear and mitochondrial, and can block the replication fork. They are antibacterial and antifungal by unknown mechanism(s). APS have shown activity against cancer cells in studies by more than one researcher. These salts are preferentially taken up by malignant cells and by mitochondria in normal cells. They have been used as carrier molecules to deliver DNA-alkylating agents into mitochondria. Some APS are inherently fluorescent. They can also be conjugated with a flurophore to enhance fluorescence and cell imaging. We have synthesized compounds and observed these effects in our laboratories. We will synthesize and purify by HPLC a small targeted library of new examples of these compounds for anti-cancer screening by collaborators here and at other institutions. Three-step high-yield protocols developed in our laboratories using readily available reagents, microwave-assisted and/or solvent-free synthesis will be employed. Anti-cancer compounds will be tested in cell-imaging and cell toxicity studies, in flourescence assays, and DNA replication-blocking experiments to gain insight into the mechanism(s) of their anti-cancer activity and general toxicity. In vitro results will be calibrated to anti-cancer screening data to search for a relationship that can prove predictive of activity for new compounds in the anti-cancer screens. The QSAR variables cLogP, molecular refractivity, polarizability, and polar surface area will be calculated and tested for correlations with activity. Relative fluorescence due to selective uptake by normal vs. malignant cells will be explored as a basis for development of a diagnostic tool. Active compounds discovered in screening will be considered for preclinical trials. Analogues of active compounds will be syntesized and screened. Four students can work in this project with stipend, supplies and equipment support during the year of funding. Others may participate while taking independent study for course credit. Success at any level in any of the research areas will provide opportunities for four to six students per year to continue past the first year of the project. This will be supported by future grants and/or students taking independent study for credit.

News & Events

Newsletter

RI-INBRE Newsletter Winter 2013

Grant Workshop PowerPoint Presentations & Handouts

Balancing Teaching and Research at PUIs


Components of a Successful AREA (R15) Grant


NSF-RUI Program: Strategies and Tips for Success


Handouts

Important Dates & Announcements

RI-INBRE Calendar


RI-INBRE News


NIH Public Access Policy


NIH R15 Submission Deadlines - June 25, October 25, & February 25

3/22/2013 - "Revealing Nonobvious Features in Noncoding Human DNA - Insights for Evolution, Gene Expression and Disease" by Laura Elnitski, Ph.D., National Human Genome Institute, National Institutes of Health


8/14/2013-8/16/2013 - 5th Northeast Regional IDeA Meeting, University of Delaware, Newark, DE


4th Northeast Regional IDeA Meeting, Salve Regina University, Newport, RI


RI Inbre Research Fellows

Promote Your Page Too  

 
 

 

INBRE Menu
Supported by grant # 8P20GM103430-12 from the National Institute of General Medical Sciences of the National Institutes of Health.
Contact Info
Contact RI INBRE:  
University of Rhode Island
495J, College of Pharmacy
| 7 Greenhouse Road | Kingston, RI 02881
Phone: (401) 874-9288 | Fax: (401) 874-2646 | E-mail: riinbre@etal.uri.edu